DS-437 is a dual PRMT5/7 inhibitor (IC50s: 6 μM). DS-437 also inhibits DNMT3A and DNMT3B (IC50s: 52 and 62 μM). DS-437 inhibits the methylation of FOXP3.

DS-437 increased total CD8+?and CD8+ PD-1+ T cells [2]. DS-437 was able to inhibit the methylation of an H4[1–24] peptide by the PRMT5–MEP50 complex under balanced conditions (cofactor and substrate concentrations set at their respective?Km?values) in a dose-dependent manner (IC50: 5.9 μM) [1].

The combination of DS-437 and the anti-p185erbB2/neu?antibody 4D5 had even more dramatic effects. DS-437 (10 mg/kg; i.p.; 5 times a week) has some beneficial effects on inhibiting tumor growth [1].

1674364-87-4

C15H23N7O4S

397.45

DS-437

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years